1 / 22

Alyssa Speier, MS, CIP Associate Director Regulatory Affairs & Research Compliance

What is (and isn’t) human subjects research? When do we need to cede review? New Single IRB policy; ESTR Tips & Tricks. Alyssa Speier, MS, CIP Associate Director Regulatory Affairs & Research Compliance Email: aspeier@hsph.harvard.edu Tel. 617-432-2140. Agenda. Who we are

colivia
Download Presentation

Alyssa Speier, MS, CIP Associate Director Regulatory Affairs & Research Compliance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. What is (and isn’t) human subjects research? When do we need to cede review? New Single IRB policy; ESTR Tips & Tricks Alyssa Speier, MS, CIP Associate DirectorRegulatory Affairs & Research Compliance Email: aspeier@hsph.harvard.edu Tel. 617-432-2140

  2. Agenda • Who we are • Human Subjects Research • NIH sIRB Policy • OHRA reliance/ceding practices • Resources • ESTR (Kim Serpico)

  3. Who we are

  4. Harvard University Faculty of Medicine Institutional Official Pam Caudill, Chief of Research and Administrative Operations Harvard T.H. Chan School of Public Health Institutional Official Delia Wolf, Associate Dean for Regulatory Affairs & Research Compliance Office of Human Research Administration Managing Director Leslie Howes IRB Operations Assistant Director Kim Serpico Quality Improvement Program Associate Director, ORARC Alyssa Speier Sr. IRB Review Specialist Keren-Nicole Insalaco IRB Review Specialists Jada Dixon Alma Castro Grace Bullock Sr. QA/QI Specialist Lisa Gabel QA/QI Specialist Scott Meyers Version Date 9-26-2016

  5. Human Subjects Research

  6. Why Care? HHS Policy for Protection of Human Research Subjects (45 CFR 46) “…applies to all research involving human subjects…”

  7. Research “…a systematicinvestigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge…”

  8. Human Subjects Research (HSR) Research with “a living individual about whom an investigator conducting research obtains (1) data through intervention or interaction with the individual; or (2) identifiable private information” Intervention Physical procedures or manipulations of the subject/subject's environment InteractionCommunication or interpersonal contact Private Info Information in which one can assume no observation or recording is taking place; information which has been provided for specific purposes and which will not be made public

  9. Common Examples Human Subjects Research Not Human Subjects Research Animal research Literature search Exercises solely to fulfill course requirements or to train students Program evaluation Analyses of anonymized or de-identified data (i.e., data set obtained includes no identifiers) • Clinical trial designed to evaluate the safety/efficacy of an investigational product (IND/IDE study) • Interviewing community members to evaluate the reception of a new bicycle pathway in the community • Medical record/chart review

  10. Determining HSR • Investigators may determine whether activities constitute human subjects research • Harvard LMA IRB is available to make formal determinations (submission required) • Recommended when activities are federally funded, publication anticipated, and/or activities proposed by student-investigators

  11. NIH single IRB Policy

  12. NIH single IRB Policy • 6/21/2016 – NIH issued its Final Policy on the Use of a Single IRB for Multi-Site Research: “…establishes the expectation that all sites participating in multi-site studies involving non-exempt human subjects research funded by NIH will use a single IRB to conduct ethical review required by the DHHS regulations…”

  13. Applicability • NIH funded (e.g., grant, cooperative agt., contract, or NIH intramural Research Program) • Excludes: career development, research training or fellowship awards • Involves multiple sites (“participating sites”) • Domestic • Implementing “same” protocol

  14. Exceptions to Policy • Review prohibited by a federal, tribal, or state law, regulation, or policy • Requires compelling justification • NIH expected to outline process for requests • Policy does not prohibit participating sites from duplicating review (NIH funds may not cover related costs)

  15. Effective Date • Competing grant applications (new, renewal, revision, or resubmission) with receipt dates of 9/25/2017 * or later; • Ongoing, non-competing awards not expected to comply until grantee submits a competing renewal application *Updated in the Federal Register on 12/16/2016

  16. Recent Update – 12/16/2016 • Extended effective date • Guidance from NIH now available: • http://osp.od.nih.gov/office-clinical-research-and-bioethics-policy/clinical-research-policy/models-irb-review

  17. Reliance/Ceding Practices at OHRA/Harvard LMA IRB

  18. Reliance Agreements • Process whereby one institution relies on another for IRB review/continuing oversight • Common nomenclature • ceding, cedes, reliance, IRB Authorization Agreements (IAAs), sIRB, central IRB, etc. • OHRA regularly pursues reliance agreements for multi-site non-exempt human research • Regardless of funding

  19. Serving as Reviewing IRB • Aka Institituion/IRB of Record, sIRB, etc. • No specific criteria, but appropriate when • HMS/HSDM/HSPH engaged in non-exempt human research • E.g., HMS/HSDM/HSPH in direct receipt of HHS funding; Harvard LMA School agents involved in interventions/interactions with participants, obtain informed consent, and/or access identifiable data

  20. Serving as Relying IRB • Aka Relying Institution/IRB, participating site, etc. • Specific criteria outlined in our HRPP Plan (available at https://www.hsph.harvard.edu/ohra/hrpp-plan/) • Designated IRB must hold a valid FWA AND one of the following: • The IRB has been designated as the single IRB (“sIRB”) as per the NIH Policy. • Institution is Harvard Catalyst affiliate/joinder of Harvard Catalyst reliance agreement • Institution is AAHRPP accredited • The Harvard Investigator(s) is a collaborator and human research primarily conducted at another organization (Harvard investigators are not interacting/intervening with participants) • Harvard LMA School engaged solely because it’s receiving federal funds

  21. To Request Reliance • Contact OHRA to determine appropriateness • Submit to the IRB • “Create New Study” in ESTR (https://irb.harvard.edu) • General guidance: http://estrsupport.fss.harvard.edu/creating-new-study • When Harvard Catalyst affiliate/joinder involved, also submit a “cede request” through their system (http://catalyst.harvard.edu/services/irbcede/)

  22. OHRA Resources • Reliance/Cede-related questions: • Scott Meyers (scmeyers@hsph.harvard.edu) • Department-assigned IRB Review Specialist (https://www.hsph.harvard.edu/ohra/department-assignments/) • Quality Improvement Program • Service Request (https://harvard.az1.qualtrics.com/jfe/form/SV_9Hx4AQ5p974GvMF)

More Related